Pfizer ups COVID-19 vaccine revenue estimates again as total deliveries pass one billion doses
Pfizer has upped its COVID-19 vaccine revenue estimates for 2021 from $26bn to $33.5bn, with potential for the figure to rise further.
Pfizer has upped its COVID-19 vaccine revenue estimates for 2021 from $26bn to $33.5bn, with potential for the figure to rise further.
A study of more than a million vaccinated people has found 'similar safety profiles' for the AstraZeneca and Pfizer/BioNTech vaccines: adding the incidence of rare blood clots was far higher among people with COVID-19 than those who had received either...